BA in molecular biology with Honors and Phi Beta Kappa from the University of California, Berkeley. He received his MD with Alpha Omega Alpha from the University of California, San Francisco. He received his masters in biomedical informatics from Harvard Medical School. Dr. Natarajan completed internal medicine residency at the Brigham and Women’s Hospital, then cardiology fellowship in cardiovascular medicine at the Massachusetts General Hospital.Dr. Natarajan uses germline and somatic genetic variation to uncover new biology and enable enhanced clinical care for cardiovascular disease. He leads several consortia to use genetic epidemiology, large-scale sequencing studies, genotype-driven human investigation, and genetic testing implementation. His research program spans the MGH Cardiovascular Research Center, MGH Center for Genomic Medicine, and Broad Institute Cardiovascular Disease Initiative. He is an Associate Editor for JAMA Cardiology and Science Advances. In tandem his research efforts, Dr. Natarajan oversees clinical and training programs on the prevention of cardiometabolic diseases leading the MGH Cardiovascular Disease Prevention Center, and enables novel care paradigms across the healthsystem via Mass General Brigham Personalized Medicine.Dr. Natarajan is an Elected Member of the American Society for Clinical Investigation and of the Association of American Physicians. He has received several awards for his scientific contributions, including the Jeffrey M. Hoeg and Joseph A. Vita Awards from American Heart Association, as well as mentorship awards from MGH and Harvard Medical School.

so many specialities.  This has allowed him to see connections between pathways and diseases that perhaps are not visible to all.   He has contributed to over 1400 papers, with more than 200K citations, and participated in over 30 clinical trials.  His expertise has moved increasingly into obesity given its link to many cardiometabolic outcomes.  He has received multiple awards and contributed to several major journal as associate editor including Circulating and Diabetes Care. Lastly, his driving force is a family history of diabetes and premature CVD for which he tries his best to be active and eat well but it’s a challenge!

.

two national MRFF funded clinical trials to optimize the detection of advanced liver disease in primary care. He is chair of the GESA consensus steering committee for the assessment of fatty liver disease in primary care, and has served on numerous journal editorial boards, faculties and committees within GESA, the Australian Diabetes Society, Cancer Council Australia, the American Gastroenterology Association and American Association for the Study of Liver Disease. 

University of Melbourne. He has had a long-standing interest in the management of chronic conditions in General Practice especially diabetes and heart disease. He enjoys teaching medical students, GP registrars and General Practitioners.

She collaborates with basic researchers exploring mechanisms of satiety, NASH and oesophageal cancer. She is Program Director of Surgical Services and Professor/Chair of Monash University Department of Surgery at Alfred Health Melbourne, Clinical Director of the ANZ Bariatric Surgery Registry, Chair of the Victorian Perioperative Consultative Council Surgical Sub-Committee, Past President of OSSANZ and ANZGOSA, Past Senior Examiner in General Surgery for the RACS, Past- Chair of the Scientific Committee and Global Registry of IFSO and has just been appointed Co-Deputy Head of the Monash University School of Translational Medicine.

> the ANZMOSS Integrated Health Course and serves on various committees for national and international obesity treatment organisations. He approaches obesity treatment with a patient-centred, evidence-based, goal-directed, multimodal and multidisciplinary model of care - modelled on approaches he employs for upper gastrointestinal cancer and other complex, life-threatening disease.

Liver Disease and Journal of Hepatology Reports. He was a previous Associate Editor for Journal of Hepatology and previous Chair of the Australian Liver Faculty. He has published extensively.

She is an NHMRC Fellow undertaking basic science research in the area of foetal programming of chronic disease, and she is a principal researcher in a major NHMRC funded population based project in gestational diabetes and pregnancy outcomes. She runs many clinical studies in the areas of diabetes, obesity, and hypertriglyceridaema. She currently chairs the Diabetes Clinical Advisory Group within the Northern Sydney Local Health District and is the Training Lead of the TTRA-funded Australian Centre for Accelerating Diabetes Innovations (ACADI).

Biosecurity Business Unit.  Leading a broad portfolio covering Nutrition, eHealth, Medtech and Diagnostics and Biosecurity. He has played a significant role in Australia’s response to COVID19, which he continues to do with CSIRO and the local Public Health Unit.Rob has broad ranging public health experience including;National Medical Director at BUPA Australia New ZealandNational Director Cardiovascular Health at the Heart Foundation Strategic Health Advisor to Parks Victoria Senior Medical Advisor at the Department of Health Victoria Physician in charge of travel health BHP General Practice – with considerable indigenous and rural experienceHe has held a broad range of Advisory committees. Of note, he was a member of the Safety and Quality Outcomes Committee of the Hospital Innovation Reform Council, a member of the Victorian Quality Council, Chair of General Practice Victoria, and Member of the Health Advisory Committee of the National Health and Medical Research Council.br>

research fellow at the University of Birmingham and completed MSc in Infectious Diseases with interest on viral hepatitis in pregnancy at the University of London. Damian’s PhD research in Adelaide is focused on the loss of muscle in chronic liver disease. Since moving to Adelaide Damian started South Australia’s first dedicated Fatty Liver clinic, which aims to improve management of patients with metabolic and obesity-related liver disease.

Professorial Associate with the title of Professor at the University of Melbourne, an Adjunct Professor at Monash University and at the ANU,  FAHMS,  FRACP  FAICD, FRAMA (Hon), FACHSM (Hon). He was formerly CMO and director of Nephrology at St Vincent’s Health. He will commence as the Chair of the Board of Red Cross Lifeblood and as a Board Member of the Australian Red Cross in January 2025. He is currently a Director of Kidney Health Australia and previously sat on the Boards of the Centenary Institute, Health Workforce Australia, the Florey Institute of Neuroscience and Mental Health, the Olivia Newton-John Cancer Research Institute, and the Victorian Comprehensive Cancer Centre. He is also a former President of the Australian and New Zealand Society of Nephrology and was ACT Australian of the Year in 2021.br>

He is a Fellow of the Royal Australasian College of Physicians and the American Society of Nephrology. He is internationally recognised for his expertise in cardio-kidney-metabolic medicine and is involved in the leadership of multiple large-scale trials evaluating therapeutic strategies to reduce kidney disease progression and cardiovascular events. A/Prof Neuen established the SGLT2 Meta-Analysis Cardio-Renal Trialists' Consortium, bringing together data on >90,000 patients to better understand the effects of this class of medicines in different types of patients. His work has directly informed more than 25 major international and national guidelines, position papers and scientific statements which define optimal care for people with type 2 diabetes and kidney disease including the KDIGO guidelines and American Diabetes Association Standards of Care. A/Prof Neuen is the author of over 100 peer-reviewed publications in general medical journals including The Lancet, BMJ and Nature Medicine and serves on the Editorial Boards of the American Society of Nephrology and Nephrology Dialysis and Transplantation. His work is supported by the National Health and Medical Research Council of Australia as well as philanthropic sources, and has been recognised through multiple awards, including the Royal Society of New South Wales Ida Browne Medal, and the American Heart Association's Paul Dudley White International Scholar Award.

catastrophic cardiovascular events from occurring. He is committed to solutions which improve equity across risk and management, focusing on women’s heart health and other under-served populations. His work spans the translational spectrum from the lab bench to the bedside, with a focus on understanding the factors that promote plaque formation, novel vascular imaging and leadership of large-scale clinical trials of new therapies designed to reduce the risk of heart disease.  Professor Nicholls is the 2023 recipient of the Anitschkow Prize from the European Atherosclerosis Society. He is Chair of the Asia Pacific Cardiometabolic Consortium, President of the Cardiac Society of Australia and New Zealand and a Fellow of the Australian Academy of Health and Medical Sciences.

He has led the Steering Committees of a large number of ground-breaking international clinical trials including FLOW, APPLAUSE, DUPLEX, PROTECT, CREDENCE, TESTING, ASCEND, CARMELINA and other, and leads several that are ongoing. He has received several international awards and is a Fellow of the Australian Academy of Health and Medical Sciences. He serves on the Editorial Board of the New England Journal of Medicine, and is a Highly Cited Researcher (Clarivate, top 0.1% of cited authors).

translational science and development of nephrology service and education in the Asia Pacific Region. In 2023 she was the recipient of the International Society of Nephrology AN Richards award that recognises excellence in laboratory-based research. She was recognised by the University of Sydney in 2023 with the Ruthven Blackburn Medal, which recognises the Impact of Clinical Research and the mentoring of the next generation of researchers. She is an academic nephrologist with over 440 publications in basic research and clinical medicine and over 38,000 citations. She is an inaugural Fellow of the Australian Academy of Health and Medical Sciences, was conferred a Vice Chancellors Award for Excellence in Research Supervision and recognised as a ‘Distinguished Professor’ by the University of Sydney. She was the 2014 recipient of the Ministerial Award for Excellence in Cardiovascular Research. She is Chair of Kidney Health Australia, Chair of the NSW Bureau of Health Information and Deputy Chair of the Australian Organ, Tissue and Transplant Authority. Past leadership roles include inaugural Chair of the NSW Agency for Clinical Innovation, immediate past Chair of the NSW Clinical Excellence Commission. She was Chair of the Northern Sydney Local Health District Board since its inception in 2011 till Dec 2016. She was a member of the Australian NHMRC Council from 2018-2021.

He has over 150 publications and has attracted over $12 million in research funding. Tony was awarded the Ranji and Amara Wikramanayake Clinical Diabetes Research Award in 2022. His innovated model of care for management of type 2 diabetes was recently voted the top innovation across Australia at the Health Round Table. Tony is currently President of the Australian Diabetes Society.

across the fields of MASLD, decompensated cirrhosis, hepatocellular carcinoma and viral hepatitis. A/Prof Sinclair is a regular speaker and national and international meetings, supervises multiple PhD studies in clinical research in hepatology and is regularly involved in teaching and mentoring of hepatology trainees.br>

Her main clinical interest is the intersection between type 1 diabetes, metabolic and cardiovascular health. She is involved in the conduct of adjunctive therapies clinical trials in type 1 diabetes through the Garvan Institute of Medical Research. Active or completed RCTs include the INTIMET study (metformin), RESET1 (semaglutide), TIRTLE (tirzepatide). Jen’s post-doctoral work is a supported by JDRF Australia. br>

and Alfred Health, Melbourne. Professor Zoungas is internationally recognised for her expertise in the design and conduct of large multicentre, multinational clinical trials and cohort studies which have impacted directly on public health and clinical care. She has assembled international and national teams in diabetes, cardiovascular and kidney health, including investigator lead projects and large-scale community-based clinical trials. Professor Zoungas has over 310 publications in peer-reviewed journals, including the New England Journal of Medicine, Lancet, Annals of Internal Medicine, British Medical Journal, and Nature Reviews and she is recognised as one of the most cited researcher in the field of diabetes.